The Efficacy of Spironolactone in Continuous Ambulatory Peritoneal Dialysis Patients with Hypokalemia: A Randomized Controlled Trial
Phase 3
Completed
- Conditions
- A randomized controlled trial was conducted in CAPD patients with serum potassium <3.5 mEq/L.End stage renal disease,Hypokalemia,Peritoneal dialysis,Spironolactone
- Registration Number
- TCTR20200818005
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
inclusion criteria: CAPD, age >18 years, serum k <3.5 mEq/
Exclusion Criteria
exclusion criteria: PD-related peritonitis within 1 month, Chronicdiarrhea, severe nausia and vomiting
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the efficacy of spironolactone 50 mg per day compare with placebo in CAPD patients with 8 weeks Serum potassium level
- Secondary Outcome Measures
Name Time Method Safety profile 4 and 8 week Serum potassium level